At the 4th Annual meeting of JaphMed(Japanese Association of Pharmaceutical Medicine), I gave a presentation for the audience focusing on the Medical science liaison(MSL) to increase awareness of MSL.
11. JAPhMed 2013
4th Annual Meeting
JAPhMed 2013
4th Annual Meeting
11
2006年 Forbes
米国:医師数が60万人、MR7.5万人
日本:医師数は28万人、MR6万人
Drug Makers Replace Reps With
Digital Tools
WSJ:May 10, 2011
12. JAPhMed 2013
4th Annual Meeting
JAPhMed 2013
4th Annual Meeting
12
Why pharma needs to learn the meaning of transparency
Half of 70 U.S.-based patient groups surveyed said drugmakers are innovative, and 59% said
drugmakers are good or excellent at creating high-quality, useful products. But 76% said
drugmakers have fair or poor ethics in marketing, and only 10% said the industry is transparent.
In the U.K., 70% of 80 patient groups surveyed rated drugmakers as good or excellent at making
high-quality, useful products and 72% rated ethics in industry marketing as fair or poor.
Reputationofthepharmaindustrycomparedwithotherhealthcaresectors
18. JAPhMed 2013
4th Annual Meeting
2009 MSL Survey Data Demographics
18
Kupferer, E. (2009) Medical Science Liaison (MSL) Medical Science Liaison Recruitment and Retention. MSL Quarterly,
November 2009, ISSN 1547-7886.
理科系4大卒・看護系4大卒
博士号
修士号
医学&看護&薬学系
修士・博士が86%
21. JAPhMed 2013
4th Annual Meeting
JAPhMed 2013
4th Annual Meeting
21
The data (see Figure 2), shows that 74% of surveyed companies operating in Europe now have
MSL programs, compared to 64% from a study conducted in 2010. Although this 10% boost is
significant, it is dwarfed by the increase experienced in Latin and South America. Survey
respondents reported an overall increase of 24% more MSL operations now established in that
region, from 18% in 2010 to 42% today.
http://www.pharmaphorum.com/articles/the-growing-medical-science-liaison-function
28th August 2012
The growing Medical Science Liaison function
MSL:presence of regional operations – all companies
22. JAPhMed 2013
4th Annual Meeting
5 Reasons Why the Medical Science Liaison
(MSL) Is Now More Important Than Ever
1. New drugs are going ‘boutique’
2. Genomic testing may be required
for a proper drug to achieve
3. But the genetic test may not be
ideal for the drug in question
4. Cost of drugs
5. The Orange Book on biosimilars
is missing
22
MSL, first and foremost, is an educator. He or she can share what is accurate about
a new drug, the proper patient populations for it, and the correct genetic tests to
determine who qualifies for it in the first place. Without them, there’s even more
possibility of wasted time, money and a ton of misinformation out there.
(Dr. Erin Albert http://erinalbert.com/blog/?p=5156)
23. JAPhMed 2013
4th Annual Meeting
参考文献
23
The Medical Science Liaison: An A to Z Guide,
Second Edition [Kindle版]
Cathleen Sass (著), Erin Albert (著)
eBookIt.com (2011/7/22)
The Medical Science Liaison (MSL) has been reported as
one of the best jobs over six figures for healthcare
professionals, yet is relatively unknown, even to the
medical community. What is a medical science liaison, and
what do they do? In this comprehensive must-have guide to
the role, the functions of the role are explored, along with
interviews with several MSLs, those that work around them,
and most importantly, the customers of the MSL, academic
thought leaders. Every healthcare professional, from a
pharmacist, to a PhD, to a MD, should learn more about
one of the greatest jobs that blend business with technical
and scientific acumen.